Oxurion NV Company Description

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness.

It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration.

The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.

Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Oxurion NV

Country	Belgium
Founded	1991
Industry	Biotechnology
Sector	Healthcare
Employees	20
CEO	Pascal Ghoson

Contact Details

Address: Gaston Geenslaan 1 Leuven, 3001 Belgium
Phone	32 1 675 13 10
Website	oxurion.com

Stock Details

Ticker Symbol	OXUR
Exchange	Euronext Brussels
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	BE0003846632
SIC Code	2836

Key Executives

Name	Position
Pascal Ghoson	Chief Executive Officer, Chief Financial Officer and Executive Director
Philippe Barbeaux Ph.D.	Chief Scientific Officer
Dr. Andy De Deene M.B.A., M.D.	Chief Development Officer